Drugs / IDP-120
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03003247 | Nov 2015 → Aug 2016 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02537483 | Oct 2015 → Sep 2016 | acne | Valeant Pharmaceuticals | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03664739 | Dec 2018 → Mar 2020 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03664739 ↗ |
| Route | Topical | “IDP-120 Gel, applied topically to the face once daily for 12 weeks.” NCT02537483 ↗ |